The authors report two cases of Guillain-Barré Syndrome (GBS) occurred during a national measles vaccination campaign in Izmir, Turkey. Among more than 325,000 vaccine recipients, only 2 cases of GBS were observed within the 10-week risk period. These cases yielded an incidence of 0.615 per 100,000 vaccine doses. The authors think that association between measles vaccination and GBS is coincidental, rather than causal. However, an epidemiological evaluation in Turkey is needed to clearly show that there is no causal association between measles vaccination and GBS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of measles clusters/outbreaks during 2016-2017 in Oman.
IJID Reg
March 2025
Director General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman.
Objectives: The epidemiology of measles in Oman has shown a decreasing trend since the introduction of vaccines with high coverage, even at the district level. Oman achieved elimination status in 2019. Currently, measles epidemiology is characterized by a small number of imported and importation-related cases with limited spread in the community.
View Article and Find Full Text PDFThe Addis Declaration on Immunization: Assessing the Effectiveness and Efficiency of Immunization Service Delivery Systems in Africa as of the End of 2023.
Vaccines (Basel)
December 2024
World Health Organization, Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
: The Addis Declaration on Immunization (ADI) is a historic pledge aiming at increasing political will to achieve universal access to immunization services and includes ten commitments to shape the future of immunization in Africa. : To analyze African countries' performance in achieving the fourth ADI commitment, a cross-sectional retrospective study was conducted including the 54 African Member States of the World Health Organization (WHO) out of 55 African Union (AU) Member States. The fourth ADI commitment aims at increasing the effectiveness and efficiency of immunization delivery systems and has four performance indicators.
View Article and Find Full Text PDFGenetic characterization of measles virus circulating in Iran, 2021-2023.
BMC Infect Dis
January 2025
Department of Virology, School of Public Health, National Measles Laboratory (NML), Tehran University of Medical Sciences, Tehran, Iran.
Background: Measles, an ongoing public health concern, demands continuous molecular surveillance and virus characterization for elimination. Despite Iran achieving measles elimination status in 2019 through robust molecular testing and vaccination, the COVID-19 pandemic disrupted global vaccination efforts, leading to increased measles-related morbidity and mortality. This study aims to overview measles virus serological and molecular traits in Iran from 1st January 2021 to 30th April 2023.
View Article and Find Full Text PDF[Retrospective analysis in children with vaccination granuloma].
Dermatologie (Heidelb)
January 2025
Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University, München, Deutschland.
Background: Vaccine granulomas are a common (0.3-1%) adverse event (AE) of (accidentally) subcutaneously administered vaccines and specific immunotherapies containing aluminum conjugates. The clinical symptoms with persistent itching subcutaneous nodules, predominantly affect infants and young children on the lateral thigh.
View Article and Find Full Text PDFImmunisation schedule of the Pediatric Spanish Association: 2024 recommendations.
An Pediatr (Engl Ed)
January 2025
Pediatrician, Barcelona, Spain.
The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!